Allergan Gets FDA Approval for Orzurdex, Rejection for Levadex

June 30, 2014 1:55 PM

21 0

Allergan Inc. (AGN:US), the drugmaker resisting a takeover by Valeant Pharmaceuticals International Inc. (VRX:US), won U.S. approval for a treatment of vision loss in diabetics and rejection for its migraine inhaler.

The Food and Drug Administration approved Allergan’s Ozurdex, a drug for diabetic macular edema, which can cause vision loss and eventual blindness in people with diabetes, according to a regulatory filing (AGN:US) today. The agency rejected Semprana, formerly known as Levadex, an inhalable treatmen...

Read more

To category page